Oxybutynin

Oxybutynin has been studied in 23 papers since 2021: 1 trial and 8 observational studies in people, 4 in animals, 10 reviews; 8 in the past year. It is an approved medicine. The newest story, Nov 6, 2026: “Bladder drugs presumed safer not linked to lower dementia risk”.

InterventionApproved 1975

23 papers study it6 more mention it16 findingsUpdated

PubChemChEBIMeSH

4 new papers in 30 daysSee all 29 papers on oxybutynin

At a glance

Independent labs found the same change in people. 9 independent labs in 7 countries; 46 trials, 3 about aging, 21 with no results posted.

“Exposure to steady-state dosing of fesoterodine 4 and 8 mg or oxybutynin 5 mg b.i.d. was not associated with any detectable effect on cognitive function”
A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder-wet Patients over the Age of 75 Years with Mild Cognitive ImpairmentEuropean urology focus2024doi:10.1016/j.euf.2024.02.005

2 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 9 independent labs in 7 countries
  • 2 findings against
  • 46 trials, 3 about aging, 21 with no results posted
  • Funders: National Institute for Health Research and others
  • 2 of 13 findings with company ties
  • 1 of 46 trials sponsored by its developers
  • Human trial1
  • Humans8
  • Animals4

Studies in people

1 study gave oxybutynin to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on cognitive function

Randomized trial1 week23 peopleBothover the Age of 75 YearsThe oldest old; Older adults; mild cognitive impairment and overactive bladderEuropean urology focus, Feb 23, 2024

What did studies of oxybutynin find?

10

Studies of oxybutynin measured 10 outcomes, among them treatment discontinuation due to adverse effects, hot flash frequency and hot flash composite score.

Treatment discontinuation due to adverse effects

upin humans1OR 2.9

1 study
  1. Oxybutynin increases treatment discontinuation due to adverse effects in humans (cancer-related and menopause-associated vasomotor symptoms) (OR 2.90, 95% CI 1.19–7.10).

    “Treatment discontinuation due to adverse effects was more frequent with oxybutynin (odds ratio 2.90, 95% confidence interval 1.19–7.10; p = 0.02; I2 = 0%)”

    Reviewcancer-related and menopause-associated vasomotor symptoms

    Oxybutynin for vasomotor symptoms across cancer-related and menopause-associated settings: A systematic review and meta-analysis of randomised control trials and observational studies

    Journal of Clinical Oncology

Hot flash frequency

downin humans1

1 study
  1. Oxybutynin decreases hot flash frequency in humans (cancer-related and menopause-associated vasomotor symptoms) (MD 3.88 episodes per day, 95% CI 2.96–4.80).

    “Hot flash frequency was significantly reduced with oxybutynin (mean difference 3.88 episodes per day, 95% confidence interval 2.96–4.80; p < 0.00001; I2 = 42%)”

    Reviewcancer-related and menopause-associated vasomotor symptoms

    Oxybutynin for vasomotor symptoms across cancer-related and menopause-associated settings: A systematic review and meta-analysis of randomised control trials and observational studies

    Journal of Clinical Oncology

Hot flash composite score

upin humans1

1 study
  1. Oxybutynin improves hot flash composite score in humans (cancer-related and menopause-associated vasomotor symptoms) (MD 8.81, 95% CI 6.51–11.10).

    “Oxybutynin was associated with a significant improvement in hot flash composite score compared with control (mean difference 8.81, 95% confidence interval 6.51–11.10; p < 0.00001; I2 = 54%).”

    Reviewcancer-related and menopause-associated vasomotor symptoms

    Oxybutynin for vasomotor symptoms across cancer-related and menopause-associated settings: A systematic review and meta-analysis of randomised control trials and observational studies

    Journal of Clinical Oncology

Cognitive function

no changein humans1

1 study
  1. Oxybutynin showed no clear effect on cognitive function in humans (mild cognitive impairment and overactive bladder).

    “Exposure to steady-state dosing of fesoterodine 4 and 8 mg or oxybutynin 5 mg b.i.d. was not associated with any detectable effect on cognitive function”

    Human trialmild cognitive impairment and overactive bladder5 mg b.i.d.1 weekn = 23

    A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder-wet Patients over the Age of 75 Years with Mild Cognitive Impairment

    European urology focus

Urgency and urge incontinence

downin humans1

1 study
  1. Oxybutynin decreases urgency and urge incontinence in humans (postmenopausal women; compared with placebo).

    “A randomized controlled trial demonstrated that oxybutynin was significantly better than placebo at improving postmenopausal urgency and urge incontinence.”

    Reviewpostmenopausal women; compared with placebofemales

    Treatment of urge incontinence in postmenopausal women: A systematic review

    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica

Frailty phenotype

upin mice1

1 study
  1. Oxybutynin increases frailty phenotype in mice (aRR 1.48, 95% CI 1.01-2.16).

    “oxybutynin (aRR = 1.48; 95% CI 1.01-2.16) and citalopram monotherapy (aRR = 1.96; 95% CI 1.41-2.74), p < 0.05”

    Animalsfeed and/or watermales

    Preclinical frailty assessments: Phenotype and frailty index identify frailty in different mice and are variably affected by chronic medications

    Experimental gerontology

More on Frailty phenotype

Dementia

no changein humans1

1 study
  1. Oxybutynin was not clearly linked with dementia in humans (compared with mirabegron).

    “No effect was seen with oxybutynin or trospium.”

    Humanscompared with mirabegron

    Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study

    European urology focus

More on Dementia

Fall or fracture

no changein humans1OR 1.19

1 study
  1. Oxybutynin was not clearly linked with fall or fracture in humans (first 30 days compared to beta-3 agonist users) (OR 1.19, 95% CI 0.95-1.49).

    “or falls/fractures (oxybutynin users OR 1.19 [95% CI 0.95-1.49], newer OAB anticholinergic users OR 1.14 [95% CI 0.91-1.43]) compared to beta-3 agonist users.”

    Humansfirst 30 days compared to beta-3 agonist users30 daysn = 103,024

    The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications

    Neurourology and urodynamics

Delirium

no changein humans1OR 1.28

1 study
  1. Oxybutynin was not clearly linked with delirium in humans (first 30 days compared to beta-3 agonist users) (OR 1.28, 95% CI 0.84-1.96).

    “there was no significantly increased risk of either delirium (oxybutynin users OR 1.28 [95% CI 0.84-1.96], newer OAB anticholinergic users OR 0.92 [95% CI 0.58-1.46])”

    Humansfirst 30 days compared to beta-3 agonist users30 daysn = 103,024

    The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications

    Neurourology and urodynamics

More on Delirium

Memory and attention

downin humans1

1 study
  1. Oxybutynin impairs memory and attention in humans.

    “Short-term randomized clinical trials demonstrated that the administration of the anticholinergic oxybutynin leads to impaired memory and attention”

    ReviewShort-term

    The cognitive effect of anticholinergics for patients with overactive bladder

    Nature reviews. Urology

What is oxybutynin linked with?

4

Studies link oxybutynin with 4 measures, most often dementia (3 studies).

Dementia

upin humans3OR 4.53

3 studies
  1. Oxybutynin is linked with a higher risk of dementia in humans (adjusted for age, sex, comorbidities, and psychotropic drug use) (OR 4.53, 95% CI 2.18-9.42).

    “Among individual OAB anticholinergics, the ORs for oxybutynin (4.53; 95% CI: 2.18-9.42, p < 0.0001) and tolterodine (5.64; 95% CI: 2.42-13.17, p < 0.0001) were significant”

    Humansadjusted for age, sex, comorbidities, and psychotropic drug use

    Associations between Anticholinergic Use and Dementia Risk in a Prevalent-User Cohort: Analysis of Japanese Medication Histories as Real-World Data

    Biological & pharmaceutical bulletin

  2. Oxybutynin is linked with a higher risk of dementia in humans (adjusted odds ratio 1.31, 95% CI 1.21 to 1.42).

    “The risk of dementia was substantially increased with the use of oxybutynin hydrochloride (adjusted odds ratio 1.31, 95% CI 1.21 to 1.42 and 1.28, 1.15 to 1.43”

    Humans366-1095 total standardised daily doses

    Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study

    BMJ medicine

  3. Oxybutynin is linked with a higher risk of dementia in humans.

    “particularly marked increased risk of dementia for oxybutynin and solifenacin”

    Humans

    Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database

    The Journal of urology

More on Dementia

Central nervous system adverse effects

upin humans1

1 study
  1. Oxybutynin is associated with central nervous system adverse effects in humans among drugs used to treat overactive bladder (highest risk among drugs used to treat overactive bladder).

    “the highest risk of adverse effects on the central nervous system was observed with oxybutynin.”

    Reviewamong drugs used to treat overactive bladdercentral nervous system

    Overactive bladder: cognitive effects of antimuscarinics

    Femina

Mortality

upin humans1

1 study
  1. Oxybutynin raises the risk of mortality in humans (26-58%).

    “oxybutynin is associated with a significantly higher risk of mortality of 26-58% in comparison to other OAB anticholinergic medications or β3 agonists.”

    Review

    The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists

    European urology focus

Fall or fracture

upin humans1HR 1.13

1 study
  1. Oxybutynin is linked with a higher risk of fall or fracture in humans (continuous usage compared to beta-3 agonist users) (HR 1.13, 95% CI 1.02-1.24).

    “and an increased HR for fall/fracture among oxybutynin users (HR 1.13, 95% CI 1.02-1.24).”

    Humanscontinuous usage compared to beta-3 agonist userscontinuous usagen = 103,024

    The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications

    Neurourology and urodynamics

Has oxybutynin been tested in people?

3 of 46 about aging

Yes: 1 trial and 8 observational studies in people have been published, and 45 trials are registered.

Approved

All 8

Repurposing

All 22

Every condition in trials

  • Neurogenic Urinary Bladder

    Phase 4Results posted2 trials

  • Cognition

    Phase 4Completed1 trial

  • Memory

    Phase 4Completed1 trial

  • Obstructive sleep apnea of adult

    Phase 4Completed1 trial

  • Male urogenital diseases

    Phase 2Recruiting1 trial

  • Prostatic neoplasm

    Phase 2Results posted1 trial

All 8

Stopped

  • NCT05658874TerminatedInterstitial cystitis

    unable to reach the recruitment numbers required to power our primary outcome

Who is developing oxybutynin?

3 companies: AbbVie, Alza Corporation, DE, USA and Mylan Pharmaceuticals.

Companies
  • AbbViePhase 4overactive detrusor, neurogenic bladder
  • Alza Corporation, DE, USAPhase 3urinary incontinence
  • Mylan PharmaceuticalsPhase 1

Trial sponsors

Funding

1 grant since 2022

National Institute for Health Research£2M

Contains public sector information licensed under the Open Government Licence v3.0.

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 1Jun 2026: 0Jul 2026: 1Aug 2026: 0Sep 2026: 0Oct 2026: 2Nov 2026: 39 papers in 12 months
JAMA Network Open

Bladder drugs presumed safer not linked to lower dementia risk

Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.

Cohort · 830,393 peopleIncident dementia

See all 29 papers on oxybutynin